Analyst Tyler Van Buren from TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report) and decreased the price target to $970.00 from $1,030.00.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Tyler Van Buren has given his Buy rating due to a combination of factors influencing Regeneron’s performance. Despite some short-term challenges, such as the anticipated negative impact on Eylea’s first quarter from inventory adjustments, Van Buren is optimistic about the company’s potential for growth. Regeneron’s commitment to research and development, with several promising readouts expected in the second half, underpins this positive outlook.
Additionally, Van Buren highlights the company’s financial strategies, including a new dividend and an expanded share repurchase program, as contributing to its strong bottom-line performance. The robust growth of the Eylea franchise and the anticipated positive effects of Dupixent’s launches in new indications, such as COPD and CSU, are expected to drive significant year-over-year growth. These factors collectively support Van Buren’s Buy rating for Regeneron’s stock.
According to TipRanks, Van Buren is an analyst with an average return of -0.6% and a 40.21% success rate. Van Buren covers the Healthcare sector, focusing on stocks such as Regeneron, BridgeBio Pharma, and Arcutis Biotherapeutics.
In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $1,152.00 price target.